Research Topics & Thematic Intelligence Pillars | SinoBioData

Cellular Therapeutics & Immuno-OncologyPillar Hub

CAR-T Cell Therapy in China: Exhaustion Reversal, Solid Tumor Targeting & Universal Allogeneic Platforms

Clinical trial outcomes, dual-targeting CD19/CD22 constructs, and CRISPR-edited allogeneic (off-the-shelf) CAR-T developments across major Chinese research hospitals.

Overall Response Rate (MM BCMA CAR-T)

98.8%

Complete Response Rate (Gastric Claudin18.2)

57.1%

Explore Full Intelligence Report & Papers

Biologics & Targeted OncologyPillar Hub

Antibody-Drug Conjugates (ADCs): Novel Cleavable Linkers, Topoisomerase I Payloads & Bispecific Delivery

Analysis of China’s surge in out-licensing multi-billion-dollar ADC assets targeting HER2, Trop-2, Claudin18.2, and B7-H3 to Western pharmaceutical giants.

Drug-to-Antibody Ratio (DAR)

7.8 - 8.0

Serum Stability Half-Life

> 14 Days

Explore Full Intelligence Report & Papers

Genomics & Gene EditingPillar Hub

Precision Gene Editing: Cytosine/Adenine Base Editors & In-Vivo Delivery for Genetic Diseases

Evaluating high-fidelity base editors, Cas12a variants, and lipid nanoparticle (LNP) in-vivo delivery systems engineered by Chinese academic laboratories.

On-Target Base Editing Efficiency

> 88%

Off-Target Indel Frequency

< 0.05%

Explore Full Intelligence Report & Papers

Biomedical & Genomic Intelligence Pillars

CAR-T Cell Therapy in China: Exhaustion Reversal, Solid Tumor Targeting & Universal Allogeneic Platforms

Antibody-Drug Conjugates (ADCs): Novel Cleavable Linkers, Topoisomerase I Payloads & Bispecific Delivery

Precision Gene Editing: Cytosine/Adenine Base Editors & In-Vivo Delivery for Genetic Diseases